1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Castration Sensitive Prostate Cancer: new trials by email Literature Review of Castration Sensitive Prostate Cancer trials Research Report on Castration Sensitive Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Testing if Patients With Advanced Prostate Cancer Who Are Responding Well to Combination Treatment Can Safely Reduce Their Medication to a Single Hormone Therapy, Compared to Continuing Their Current Drugs De-escalation strategy, Continuation of initial Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitor (ARPI) combination therapy at standard doses - Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer | Phase 2 | Not yet recruiting | Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute | 170 | 2026-09-01 | 2026-10-07 |
| Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) Recurrence-directed therapy (RDT), ELIGARD 22.5mg - Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer | Phase 2 | Recruiting | Ontario Clinical Oncology Group (OCOG) | 162 | 2026-05-06 | 2026-10-13 |
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Androgen Antagonists (1) · luprolide acetate gel depot (1)
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute (1) · Ontario Clinical Oncology Group (OCOG) (1)
Canada (1) · India (1)
Jim Wright, Dr. (1) · Theos Tsakiridis, Dr. (1)